MedTrace Logo

Trial of Levomilnacipran in Geriatric Depression

NCT02466958 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-08-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults.

Conditions

Interventions

DRUG

levomilnacipran

antidepressant

DRUG

Placebo

an inactive drug

Sponsors & Collaborators

Principal Investigators

  • Helen Lavretsky, M.D. · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-12-09
Completion
2018-12-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02466958 on ClinicalTrials.gov